Cell/Gene Tx channel feed

Avro­bio ends all de­vel­op­ment, search­es for life af­ter re­cent gene ther­a­py sale to No­var­tis

2 months ago
People

Ten­point Ther­a­peu­tics launch­es with $70M to re­store vi­sion with stem cell ther­a­pies and ‘re­pro­gram­ming’ med­i­cines

2 months ago
Financing
Startups

Tes­sa en­joyed big back­ers, great sci­ence and world-class am­bi­tion. So what did we learn from its col­lapse?

2 months ago
Bioregnum

Astel­las eyes rare oph­thal­mol­o­gy, li­cens­ing 4DMT's vi­ral vec­tor for gene ther­a­py for up to $962M

2 months ago
Deals

Pfiz­er in­vests $25M in­to Cari­bou Bio­sciences, gets first dibs on off-the-shelf CAR-T ther­a­py for mul­ti­ple myelo­ma

2 months ago
Deals

Sin­ga­pore can­cer cell ther­a­py start­up Tes­sa Ther­a­peu­tics to shut down

2 months ago
People

HTA changes at EU lev­el could slow the up­take of new cell and gene ther­a­pies, in­dus­try group warns

2 months ago

Chi­na ap­proves BC­MA CAR-T ther­a­py for mul­ti­ple myelo­ma, with In­novent beat­ing Leg­end in race to be first

3 months ago
China

Eli Lil­ly to buy di­a­betes cell ther­a­py part­ner Sig­ilon, ex­pand­ing bet on pre­clin­i­cal pro­gram

3 months ago
Deals
Pharma

In a first, FDA signs off on Cell­Tran­s' type 1 di­a­betes cell ther­a­py days af­ter in­dus­try's eyes fix­at­ed on Ver­tex da­ta

3 months ago
R&D
FDA+

Gene ther­a­py biotech Cap­si­da lays off work­ers af­ter ex­pand­ing Ab­b­Vie pact, adding Lil­ly col­lab

3 months ago
People
Startups

Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

3 months ago
R&D

A French start­up wants to de­cen­tral­ize cell and gene ther­a­py man­u­fac­tur­ing, mak­ing it 'the size of a book'

3 months ago
Financing
Manufacturing

Off-the-shelf and on the de­cline: Adicet Bio’s shares halved af­ter PhI look at cell ther­a­py

3 months ago
R&D

Nkar­ta breaks si­lence on CAR-NK ther­a­py for AML af­ter a year, shares tum­ble

3 months ago
R&D

Lon­za, Ver­tex to build a new cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty for the biotech’s type 1 di­a­betes ther­a­pies

3 months ago
Manufacturing

FDA's Pe­ter Marks over­rode re­view­ers’ call to re­ject Sarep­ta’s new Duchenne gene ther­a­py

3 months ago
FDA+

Sarep­ta's gene ther­a­py to be man­u­fac­tured at Catal­ent plant with 'op­er­a­tional chal­lenges' this spring

3 months ago
Manufacturing

CAR-T cell ther­a­py for myas­the­nia gravis shows promise in small study by Carte­sian Ther­a­peu­tics

3 months ago
R&D

Up­dat­ed: FDA ap­proves Sarep­ta’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py via ac­cel­er­at­ed path­way

3 months ago
Pharma
FDA+

Cor­rect­ed: Prime Med­i­cine part­ners with Ver­sant-backed biotech to de­vel­op safer stem cell trans­plants

3 months ago
Deals

Sarep­ta's gene ther­a­py for Duchenne ex­pect­ed to get FDA rul­ing to­day

3 months ago
FDA+

Por­tal In­no­va­tions to call Hous­ton its third home, with CAR-T start­up March Bio­sciences al­ready in the port­fo­lio

3 months ago
Financing
Startups

Ul­tragenyx opens new gene ther­a­py man­u­fac­tur­ing site in Mass­a­chu­setts

3 months ago
Manufacturing
First page Previous page 123456 Next page Last page
A service from the Financial Times